Cargando…
Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis
BACKGROUND: Standard treatment for stage I or non-bulky stage II diffuse large B-cell lymphoma (DLBCL) has been either a brief course of chemotherapy plus involved-field radiotherapy (IFRT) or prolonged cycles of chemotherapy. The introduction of rituximab has necessitated re-evaluation of the treat...
Autores principales: | Hong, Junshik, Kim, Ae Jin, Park, Jin Sun, Lee, Seok Ho, Lee, Kyu Chan, Park, Jinny, Sym, Sun Jin, Cho, Eun Kyung, Shin, Dong Bok, Lee, Jae Hoon |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023051/ https://www.ncbi.nlm.nih.gov/pubmed/21253427 http://dx.doi.org/10.5045/kjh.2010.45.4.253 |
Ejemplares similares
-
Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy
por: Hong, Junshik, et al.
Publicado: (2014) -
Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009) -
R-CHOP-Associated Graves' Hyperthyroidism
por: Mora, Natalie, et al.
Publicado: (2019) -
R-CHOP versus CHOP in HIV-associated lymphoma: a meta-analysis of prospective studies
por: Echenique, Ignacio, et al.
Publicado: (2012) -
Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
por: Guo, Wei, et al.
Publicado: (2015)